GALT · GALECTIN THERAPEUTICS INC

📄 Latest SEC Filings in Plain English

• Aug 14, 2026 · Quarterly report for the period ended Jun 30, 2026
  Form 10-Q · SEC filing
• Aug 14, 2026 · Earnings Reported Q2 2026 results: $13.2 million cash as of June 30, 2026, net loss of $9.2 million or $0.14 per share. Reached FDA agreement on key Phase 3 belapectin trial elements; protocol submission expected 3Q 2026. Chairman converted $105.8 million of debt into 34,376,167 common shares.
  Form 8-K · SEC filing · Press release

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

• Mar 2022 · Phase 1 · Results Expected · GT-032 Belapectin Hepatic Impairment
  Registry primary completion date, not a results date
• Mar 2018 · Phase 2 · Results Expected · An Open-Label, Phase 2a Study to Evaluate Safety and Efficacy of GR-MD-02 for Treatment of Psoriasis
  Registry primary completion date, not a results date
• Oct 2017 · Phase 2 · Results Expected · Clinical Trial to Evaluation the Safety and Efficacy of GR-MD-02 for the Treatment of Liver Fibrosis and Resultant Portal Hypertension in Patients With Nash Cirrhosis
  Registry primary completion date, not a results date
• Sep 2016 · Phase 2 · Results Expected · Clinical Trial to Evaluate Efficacy of GR-MD-02 for Treatment of Liver Fibrosis in Patients With NASH With Advanced Fibrosis
  Registry primary completion date, not a results date
• Feb 2015 · Phase 1 · Results Expected · Phase 1 Study to Evaluate Safety of GR-MD-02 in Subjects With Non-Alcoholic Steatohepatitis (NASH) and Advanced Fibrosis
  Registry primary completion date, not a results date
• Apr 2005 · Phase 1 · Results Expected · Safety of GM-CT-01 With and Without 5-Fluorouracil in Patients With Solid Tumors
  Registry primary completion date, not a results date

📊 Drug Pipeline

Also used in these trials (approved or third-party drugs, not GALT's own candidates): Ipilimumab, Pembrolizumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

GALT holds $13.3M in cash and short-term investments (as of Jun 30, 2026) and burns about $3.2M/quarter from operations, an estimated runway of 12.6 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 68 · High

• Cash runway 13 months +18
• ATM program on file since Mar 2026 +15
• Shelf registration (S-3, Mar 2026) +10
• Going-concern doubt in the latest 10-Q +15These factors raise substantial doubt about the Company’s ability to continue as a going concern for a period of 12 months from the issuance date of these financial statements. 10-Q, Aug 2026
• Share count +57% in a year +20
• Raised after last reported balance sheet (Aug 2026) -10

Recent financing filings on SEC EDGAR:

• Aug 4, 2026 · Private placement (8-K Item 3.02) · 8-K
• Mar 31, 2026 · Shelf registration with ATM program, up to $200M · S-3

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GALT files for a raise →

👥 Who Owns GALT

Share count 100,849,644 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.